Table 2.
Correlation of CTC count and phenotype with clinicopathological variables.
| Variable | N | T-CTC | M-CTC | E-CTC | Bi-CTC |
|---|---|---|---|---|---|
| P value | P value | P value | P value | ||
| Age | |||||
| <70 | 30 | 0.30 | 0.46 | 0.45 | 0.43 |
| ≥70 | 24 | ||||
| PSA at diagnosis | 54 | 0.33 | 0.46 | 0.44 | 0.95 |
| Pathologic Gleason score | |||||
| ≤7 | 13 | 0.12 | 0.30 | 0.92 | 0.34 |
| 8 | 14 | ||||
| ≥9 | 27 | ||||
| pT stage | |||||
| T2a-T3a | 16 | 0.19 | 0.066 | 0.86 | 0.86 |
| T3b | 21 | ||||
| T4 | 17 | ||||
| pN stage | |||||
| N0 | 30 | 0.014 | 0.087 | 0.18 | 0.027 |
| N1 | 24 | ||||
| Surgical margin | |||||
| positive | 36 | 0.42 | 0.38 | 0.37 | 0.17 |
| negative | 18 | ||||
| Number of metastases | |||||
| 1-3 | 36 | 0.012 | 0.009 | 0.50 | 0.12 |
| 4-5 | 18 |
CTC, circulating tumor cell; T-CTC, total circulating tumor cell; M-CTC, mesenchymal circulating tumor cell; E-CTC, epithelial circulating tumor cell; Bi-CTC, biphenotypic circulating tumor cell; N, number; PSA, Prostate-specific antigen; pT stage, Pathologic T stage; pN stage, Pathologic N stage.